Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kibow Biotech has renewed its licensing and marketing agreement with the current licensing partner specializing in animal health.
Subscribe to our email newsletter
The agreement refers to ‘Azodyl’, a patented, 100% natural, probiotic dietary supplement which is used to reduce azotemia in dogs and cats with moderate to severe renal failure.
Kibow aims to use a major portion of the $2.4m funding for testing a similar, patented, probiotic dietary supplement intended for human consumption.
The product is called ‘Kibow Biotics’, an orally consumable, enteric-coated gel cap product composed of food-grade microbes (‘Probiotics’) helps in improving the quality of life in chronic kidney failure (CKF) patients.
The drug gets metabolized and the uremic toxins get diffused into the bowel as a consequence of increased levels of these toxins in the blood.
Kibow’s is set to start a human clinical trials involving dialysis and pre-dialysis patients at Mayo clinic, Rochester.